Literature DB >> 28101822

Lupinus albus Conglutin Gamma Modifies the Gene Expressions of Enzymes Involved in Glucose Hepatic Production In Vivo.

Ana E González-Santiago1, Belinda Vargas-Guerrero1, Pedro M García-López2, Alma L Martínez-Ayala3, José A Domínguez-Rosales1, Carmen M Gurrola-Díaz4.   

Abstract

Lupinus albus seeds contain conglutin gamma (Cγ) protein, which exerts a hypoglycemic effect and positively modifies proteins involved in glucose homeostasis. Cγ could potentially be used to manage patients with impaired glucose metabolism, but there remains a need to evaluate its effects on hepatic glucose production. The present study aimed to analyze G6pc, Fbp1, and Pck1 gene expressions in two experimental animal models of impaired glucose metabolism. We also evaluated hepatic and renal tissue integrity following Cγ treatment. To generate an insulin resistance model, male Wistar rats were provided 30% sucrose solution ad libitum for 20 weeks. To generate a type 2 diabetes model (STZ), five-day-old rats were intraperitoneally injected with streptozotocin (150 mg/kg). Each animal model was randomized into three subgroups that received the following oral treatments daily for one week: 0.9% w/v NaCl (vehicle; IR-Ctrl and STZ-Ctrl); metformin 300 mg/kg (IR-Met and STZ-Met); and Cγ 150 mg/kg (IR-Cγ and STZ-Cγ). Biochemical parameters were assessed pre- and post-treatment using colorimetric or enzymatic methods. We also performed histological analysis of hepatic and renal tissue. G6pc, Fbp1, and Pck1 gene expressions were quantified using real-time PCR. No histological changes were observed in any group. Post-treatment G6pc gene expression was decreased in the IR-Cγ and STZ-Cγ groups. Post-treatment Fbp1 and Pck1 gene expressions were reduced in the IR-Cγ group but increased in STZ-Cγ animals. Overall, these findings suggest that Cγ is involved in reducing hepatic glucose production, mainly through G6pc inhibition in impaired glucose metabolism disorders.

Entities:  

Keywords:  G6pc gene expression; Gamma conglutin; Hepatic glucose production; Impaired glucose metabolism; Lupinus albus

Mesh:

Substances:

Year:  2017        PMID: 28101822     DOI: 10.1007/s11130-016-0597-7

Source DB:  PubMed          Journal:  Plant Foods Hum Nutr        ISSN: 0921-9668            Impact factor:   3.921


  23 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Lupin seed γ-conglutin lowers blood glucose in hyperglycaemic rats and increases glucose consumption of HepG2 cells.

Authors:  Maria Rosa Lovati; Cristina Manzoni; Silvia Castiglioni; Anna Parolari; Chiara Magni; Marcello Duranti
Journal:  Br J Nutr       Date:  2011-06-28       Impact factor: 3.718

3.  Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa.

Authors:  H Schägger; G von Jagow
Journal:  Anal Biochem       Date:  1987-11-01       Impact factor: 3.365

Review 4.  Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes.

Authors:  Paul D van Poelje; Scott C Potter; Mark D Erion
Journal:  Handb Exp Pharmacol       Date:  2011

5.  Effects of untreated and thermally treated lupin protein on plasma and liver lipids of rats fed a hypercholesterolemic high fat or high carbohydrate diet.

Authors:  Corinna Brandsch; Diana Kappis; Kristin Weisse; Gabriele I Stangl
Journal:  Plant Foods Hum Nutr       Date:  2010-12       Impact factor: 3.921

6.  Within- and between-subject variation in commonly measured anthropometric and biochemical variables.

Authors:  A Widjaja; R J Morris; J C Levy; K N Frayn; S E Manley; R C Turner
Journal:  Clin Chem       Date:  1999-04       Impact factor: 8.327

Review 7.  Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs.

Authors:  Shivakumar Chitturi; Jacob George
Journal:  Semin Liver Dis       Date:  2002       Impact factor: 6.115

8.  Neonatal streptozotocin-induced diabetes mellitus: a model of insulin resistance associated with loss of adipose mass.

Authors:  Julie Takada; Magaly A Machado; Sidney B Peres; Luciana C Brito; Cristina N Borges-Silva; Cecília E M Costa; Miriam H Fonseca-Alaniz; Sandra Andreotti; Fabio Bessa Lima
Journal:  Metabolism       Date:  2007-07       Impact factor: 8.694

9.  Administration of Lupinus albus gamma conglutin (Cγ) to n5 STZ rats augmented Ins-1 gene expression and pancreatic insulin content.

Authors:  Belinda Vargas-Guerrero; Pedro M García-López; Alma L Martínez-Ayala; José A Domínguez-Rosales; Carmen M Gurrola-Díaz
Journal:  Plant Foods Hum Nutr       Date:  2014-09       Impact factor: 3.921

10.  Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP.

Authors:  Yong Deuk Kim; Keun-Gyu Park; Yong-Soo Lee; Yun-Yong Park; Don-Kyu Kim; Balachandar Nedumaran; Won Gu Jang; Won-Jea Cho; Joohun Ha; In-Kyu Lee; Chul-Ho Lee; Hueng-Sik Choi
Journal:  Diabetes       Date:  2007-10-01       Impact factor: 9.461

View more
  4 in total

1.  Effects on the Caco-2 Cells of a Hypoglycemic Protein from Lupin Seeds in a Solution and Adsorbed on Polystyrene Nanoparticles to Mimic a Complex Food Matrix.

Authors:  Alberto Barbiroli; Jessica Capraro; Serena Marulo; Marta Gamba; Alessio Scarafoni
Journal:  Biomolecules       Date:  2019-10-14

2.  Effect of Lupinus rotundiflorus gamma conglutin treatment on JNK1 gene expression and protein activation in a rat model of type 2 diabetes.

Authors:  Andrea Catalina Zepeda-Peña; Carmen Magdalena Gurrola-Díaz; José Alfredo Domínguez-Rosales; Pedro Macedonio García-López; Juan Carlos Pizano-Andrade; Zamira Helena Hernández-Nazará; Belinda Vargas-Guerrero
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

3.  Lupinus albus γ-Conglutin: New Findings about Its Action at the Intestinal Barrier and a Critical Analysis of the State of the Art on Its Postprandial Glycaemic Regulating Activity.

Authors:  Giuditta C Heinzl; Marco Tretola; Stefano De Benedetti; Paolo Silacci; Alessio Scarafoni
Journal:  Nutrients       Date:  2022-09-05       Impact factor: 6.706

Review 4.  Reevaluating nutrition as a risk factor for cardio-metabolic diseases.

Authors:  Patricio López-Jaramillo; Johanna Otero; Paul Anthony Camacho; Manuel Baldeón; Marco Fornasini
Journal:  Colomb Med (Cali)       Date:  2018-06-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.